Skip to main content
COCP
NASDAQ Life Sciences

Cocrystal Pharma Secures $5M Private Placement from OPKO Health, Extending Cash Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.846
Mkt Cap
$11.306M
52W Low
$0.76
52W High
$2.67
52W Position info
11% above low
Off High info
68% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

COCP is trading near its 52-week low of $0.76 (11% above the low).

Summary

Cocrystal Pharma raised $5 million in a private placement from related party OPKO Health at $0.9134 per share — a premium to the current price. The funding addresses an urgent cash need ahead of pivotal norovirus trial data later this year.


Key Events · Financing and Capital Events · COCP

  • $5M Private Placement to OPKO Health

    Cocrystal sold 5,474,053 shares at $0.9134 per share to OPKO Health, a longtime investor and related party, for gross proceeds of $5.0 million. The price represents a premium to the current $0.8463 market price.

  • Related-Party Transaction

    OPKO Health CEO Dr. Phillip Frost is Cocrystal's co-founder, director, and principal stockholder. The investment signals insider conviction but also raises governance considerations.

  • No Warrants or Derivatives

    The transaction was a straight common stock sale with no warrants or other derivative securities, avoiding the dilutive and potentially toxic terms common in distressed biotech financings.

  • Funding Extends Runway to Key Catalyst

    Proceeds will fund preclinical and clinical programs, including the lead norovirus candidate CDI-988. Topline Phase 1b data is expected by the end of Q4 2026, a critical value inflection point.


Analysis · COCP · Life Sciences

With a going-concern warning and less than 12 months of cash on hand, Cocrystal Pharma secured $5 million from longtime investor OPKO Health at $0.9134 per share — a slight premium to the current $0.8463 price. The deal is a related-party transaction: OPKO CEO Dr. Phillip Frost is Cocrystal's co-founder, director, and principal stockholder. Notably, no warrants or derivatives were included, sidestepping the toxic terms often seen in distressed biotech financings. The capital extends the runway as the company approaches a critical catalyst — Phase 1b norovirus data expected by end of 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COCP was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3M. The 52-week trading range was $0.76 to $2.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COCP - Latest Insights

COCP
Nov 16, 2026, 6:10 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.970
Real-time Price: $0.940 info
Change: -$0.030 (-3%) info
Market Cap: $18.685M info
COCP
Sep 09, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $0.940 info
Change: -$0.190 (-17%) info
Market Cap: $18.685M info
COCP
Aug 13, 2026, 7:29 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $0.940 info
Change: -$0.140 (-13%) info
Market Cap: $18.685M info
COCP
Aug 07, 2026, 5:11 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $1.06
Real-time Price: $0.940 info
Change: -$0.120 (-11%) info
Market Cap: $18.685M info
COCP
Jun 09, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.990
Real-time Price: $0.940 info
Change: -$0.050 (-5%) info
Market Cap: $18.685M info